Stock listing
Frankfurt:5VA Vaxcyte, Inc. Aktie
German listing (Frankfurt) of Vaxcyte, Inc. · home listing NASDAQ:PCVX
Follow Vaxcyte, Inc. into a list and get an email when it puts out news.
Share price · FWB:5VA
€53.00 EUR -1.00 (-1.9%)
Close on Nov 17, 2026
- Day range
- €53.00 – €53.00 EURNov 17, 2026
- Volume
- 78 sharesNov 17, 2026
- Market cap
- €8.34B EURAt the close on Nov 17, 2026 · price × 157.4M shares outstanding
- 52-week range
- €34.74 – €64.39 EURLowest and highest trades, Nov 18, 2025 – Nov 17, 2026
- Traded on an average day
- €8,897 EURMedian day 0 shares · 34 days with no trades · last 3 months, Aug 17, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PCVX · Home | $58.52 USD | -0.88 (-1.5%) | 1,128,702 | $59.16 | $59.69 | $57.60 | $59.40 | Close on Nov 18, 2026 |
| Frankfurt:5VA | €53.00 EUR | -1.00 (-1.9%) | 78 | €53.00 | €53.00 | €53.00 | €54.00 | Close on Nov 17, 2026 |
Daily closes
Last 3 months, Aug 17, 2026 – Nov 6, 2026 · FWB:5VA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €52.30 | -2.794 | -5.1% | €52.30 | €52.30 | €52.30 | 0 | |
| €55.09 | +4.264 | +8.4% | €55.09 | €55.09 | €55.09 | 0 | |
| €50.83 | -0.366 | -0.7% | €50.83 | €50.83 | €50.83 | 0 | |
| €51.19 | -1.648 | -3.1% | €51.19 | €51.19 | €51.19 | 0 | |
| €52.84 | -0.77 | -1.4% | €52.84 | €52.84 | €52.84 | 0 | |
| €53.61 | +1.901 | +3.7% | €53.61 | €53.61 | €53.61 | 378 | |
| €51.71 | -0.478 | -0.9% | €51.71 | €51.71 | €51.71 | 150 | |
| €52.19 | +1.018 | +2.0% | €52.19 | €52.19 | €52.19 | 0 | |
| €51.17 | +0.255 | +0.5% | €51.17 | €51.17 | €51.17 | 0 | |
| €50.92 | -2.266 | -4.3% | €50.92 | €50.92 | €50.92 | 2 | |
| €53.18 | +0.997 | +1.9% | €53.18 | €53.18 | €53.18 | 0 | |
| €52.19 | -3.688 | -6.6% | €52.19 | €52.19 | €52.19 | 0 | |
| €55.87 | +2.301 | +4.3% | €55.87 | €55.87 | €55.87 | 0 | |
| €53.57 | -0.692 | -1.3% | €53.57 | €53.57 | €53.57 | 0 | |
| €54.26 | -0.333 | -0.6% | €54.26 | €54.26 | €54.26 | 0 | |
| €54.60 | -2.828 | -4.9% | €54.60 | €54.60 | €54.60 | 0 | |
| €57.43 | +0.886 | +1.6% | €57.43 | €57.43 | €57.43 | 0 | |
| €56.54 | -3.219 | -5.4% | €56.54 | €56.54 | €56.54 | 0 | |
| €59.76 | -0.449 | -0.7% | €59.76 | €59.76 | €59.76 | 0 | |
| €60.21 | +5.324 | +9.7% | €60.21 | €60.21 | €60.21 | 0 | |
| €54.88 | -1.286 | -2.3% | €54.88 | €54.88 | €54.88 | 4 | |
| €56.17 | -0.181 | -0.3% | €56.17 | €56.17 | €56.17 | 5 | |
| €56.35 | -5.886 | -9.5% | €56.35 | €56.35 | €56.35 | 25 | |
| €62.24 | -2.117 | -3.3% | €62.24 | €62.24 | €62.24 | 0 | |
| €64.35 | +16.66 | +34.9% | €50.21 | €64.39 | €49.74 | 52 | |
| €47.70 | -0.699 | -1.4% | €47.70 | €47.70 | €47.70 | 1,074 | |
| €48.40 | +0.869 | +1.8% | €48.40 | €48.40 | €48.40 | 2,412 | |
| €47.53 | -0.771 | -1.6% | €47.53 | €47.53 | €47.53 | 0 | |
| €48.30 | +1.373 | +2.9% | €48.30 | €48.30 | €48.30 | 1,788 | |
| €46.93 | -0.854 | -1.8% | €46.93 | €46.93 | €46.93 | 4 | |
| €47.78 | +1.168 | +2.5% | €47.78 | €47.78 | €47.78 | 0 | |
| €46.61 | -2.284 | -4.7% | €46.61 | €46.61 | €46.61 | 321 | |
| €48.90 | -0.165 | -0.3% | €48.90 | €48.90 | €48.90 | 0 | |
| €49.06 | +0.853 | +1.8% | €49.06 | €49.06 | €49.06 | 0 | |
| €48.21 | -2.006 | -4.0% | €48.21 | €48.21 | €48.21 | 0 | |
| €50.21 | +1.561 | +3.2% | €50.21 | €50.21 | €50.21 | 200 | |
| €48.65 | -0.54 | -1.1% | €48.65 | €48.65 | €48.65 | 0 | |
| €49.19 | +0.217 | +0.4% | €49.19 | €49.19 | €49.19 | 0 | |
| €48.98 | +0.529 | +1.1% | €48.98 | €48.98 | €48.98 | 0 | |
| €48.45 | +0.214 | +0.4% | €48.45 | €48.45 | €48.45 | 470 | |
| €48.23 | -0.329 | -0.7% | €48.23 | €48.23 | €48.23 | 1,350 | |
| €48.56 | -1.05 | -2.1% | €48.56 | €48.56 | €48.56 | 0 | |
| €49.61 | -0.476 | -1.0% | €49.61 | €49.61 | €49.61 | 0 | |
| €50.09 | -4.572 | -8.4% | €50.09 | €50.09 | €50.09 | 0 | |
| €54.66 | +4.724 | +9.5% | €50.36 | €54.99 | €50.05 | 20 | |
| €49.94 | -0.244 | -0.5% | €49.94 | €49.94 | €49.94 | 4 | |
| €50.18 | 0.00 | 0.0% | €50.18 | €50.18 | €50.18 | 0 | |
| €50.18 | +0.414 | +0.8% | €50.18 | €50.18 | €50.18 | 0 | |
| €49.77 | +1.055 | +2.2% | €49.77 | €49.77 | €49.77 | 0 | |
| €48.71 | -1.029 | -2.1% | €48.71 | €48.71 | €48.71 | 103 | |
| €49.74 | +0.13 | +0.3% | €49.74 | €49.74 | €49.74 | 808 | |
| €49.61 | +0.239 | +0.5% | €49.61 | €49.61 | €49.61 | 203 | |
| €49.37 | -0.893 | -1.8% | €49.37 | €49.37 | €49.37 | 138 | |
| €50.26 | -0.532 | -1.0% | €50.26 | €50.26 | €50.26 | 0 | |
| €50.80 | +1.159 | +2.3% | €50.80 | €50.80 | €50.80 | 1 | |
| €49.64 | -1.445 | -2.8% | €49.64 | €49.64 | €49.64 | 135 | |
| €51.08 | +2.191 | +4.5% | €51.08 | €51.08 | €51.08 | 140 | |
| €48.89 | -0.135 | -0.3% | €48.89 | €48.89 | €48.89 | 1,040 | |
| €49.03 | +1.641 | +3.5% | €49.03 | €49.03 | €49.03 | 100 | |
| €47.38 | -1.017 | -2.1% | €47.38 | €47.38 | €47.38 | 0 |
- Ticker
- Frankfurt:5VA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest earnings call · Feb 24, 2026
Vaxcyte (NASDAQ:PCVX) Q4 2025 Earnings Call
Replay and transcript
Latest deck · Oct 5, 2026
Technical Presentation (October 2026)
Technical · 34 slides
Calls
Upcoming
Vaxcyte (NASDAQ:PCVX) Q3 2026 Earnings Call
Tue, Dec 01, 2026 · 9:35 AM ET
Register
Replays
Vaxcyte (NASDAQ:PCVX) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 4:30 PM ET
Watch TranscriptVaxcyte (NASDAQ:PCVX) Q4 2024 Earnings Call
Tue, Feb 25, 2025 · 1:30 PM ET
Watch TranscriptVaxcyte (NASDAQ:PCVX) Q4 2023 Earnings Call
Tue, Feb 27, 2024 · 4:30 PM ET
Watch Transcript
Latest news
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 4, 2026
Closed €55.09 (+8.4%) on Nov 5, 2026
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
Oct 9, 2026
Closed €60.21 (+9.7%) on Oct 12, 2026
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Oct 6, 2026
Closed €56.35 (-9.5%) on Oct 7, 2026
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Oct 5, 2026
Closed €64.35 (+34.9%) on Oct 5, 2026
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Sep 3, 2026
Closed €49.94 (-0.5%) on Sep 4, 2026
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 5, 2026
Closed €45.84 (+1.0%) on Aug 6, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
Jul 8, 2026
Closed €49.46 (-2.0%) on Jul 9, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Jun 2, 2026
Closed €39.02 (-2.2%) on Jun 3, 2026
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Closed €43.12 (-4.4%) on May 7, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Apr 7, 2026
Closed €48.89 (+3.0%) on Apr 7, 2026
Financings
Public offering of common stock and pre-funded warrants
Oct 9, 2026
Closed: US$500M raised · US$64 a share · Jefferies +7
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Evercore ISI (co-lead), Goldman Sachs & Co. LLC (co-lead), Guggenheim Securities (co-lead), Mizuho, BTIG
Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes
Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026
1.50% convertible senior notes due 2032
Oct 9, 2026
Closed: US$575M raised · Jefferies +8
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, Mizuho, Needham & Company, J. Wood Capital Advisors
Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes
Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026
Public offering of common stock
Feb 2, 2026
Closed: US$632.5M raised · US$50 a share · BofA Securities +7
Dealers: BofA Securities (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), Mizuho, BTIG, Needham & Company
Announced Jan 29, 2026 · Announced Jan 30, 2026 · Closed Feb 2, 2026
Decks
Technical Presentation (October 2026)
Technical · 34 slides · Oct 5, 2026
Technical Presentation (October 2026)
Technical · 35 slides · Oct 5, 2026
Investor Presentation (September 2026)
Investor deck · 80 slides · Sep 3, 2026
Q4 2025 Earnings Presentation
Earnings · 68 slides · Feb 24, 2026
Vaxcyte, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 129 in all · newest Nov 4, 2026 · oldest 2020
- Calls
- 5 calls with a replay · 5 with a transcript · latest Feb 24, 2026
- Decks
- 9 decks · latest Oct 5, 2026
Where Vaxcyte, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PCVX · Home listing | NASDAQ | United States | USD |
| gettex:5VA | gettex | Germany | EUR |
| LS Exchange:A2P6R6 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2P6R6 | Lang & Schwarz | Germany | EUR |
| Milan:1PCVX | Milan | Italy | EUR |
| BOATS:PCVX | BOATS | United States | USD |
| Frankfurt:5VA · This page | Frankfurt | Germany | EUR |
| BX Swiss:PCVX | BX Swiss | Switzerland | CHF |
| Dusseldorf:5VA | Dusseldorf | Germany | EUR |
| Hamburg:5VA | Hamburg | Germany | EUR |
| Munich:5VA | Munich | Germany | EUR |
| Stuttgart:5VA | Stuttgart | Germany | EUR |
| Tradegate:5VA | Tradegate | Germany | EUR |
| Hanover:5VA | Hanover | Germany | EUR |
| Xetra:5VA | Xetra | Germany | EUR |
Log in to ask 6ix AI your own questions about Vaxcyte, Inc.